![]() To date, the management of this disorder is limited because the drugs that are used are not well-tolerated and do not relieve the whole set of symptoms. Particularly, the sensitization of the immune cells triggers the release of cytokines and mediators that can affect different motor and neural functions, and produce pain, irritability, and hypersensitivity ( Lee and Park, 2014 Uranga et al., 2020). Indeed, it has been described that a persistently augmented presence of intraepithelial lymphocytes and enteroendocrine and mast cells in the intestinal mucosa unbalance the network that links the enteric immune defense and the nervous system and leads to the onset of IBS symptoms ( Yoo and Mazmanian, 2017 Uranga et al., 2020). Its etiology and pathophysiology are not properly understood, but gastrointestinal dysmotility, compromised gut barrier function, altered intestinal immune activation and visceral hypersensitivity are associated with its development ( Lee and Park, 2014). Moreover, 50%–90% of the patients present psychiatric comorbidities, including anxiety, social phobia, somatization disorder, major depressive disorder, or posttraumatic stress ( Banerjee et al., 2017). It is distinguished by recurrent abdominal pain, bloating, cramping, gas and altered bowel habits as per the diagnostic Rome IV criteria ( Mearin et al., 2016 Weaver et al., 2017). IBS is a very prevalent functional digestive disease, being its worldwide prevalence of 11% ( Mearin et al., 2016). These beneficial effects may be due to the inhibition of mast cells degranulation and serotonin pathway. Lastly, SHE also seems to modulate the serotonin pathway by restoring the altered expression of the 5-HT receptors Htr-3 and Htr-4.Ĭonclusion: SHE could be considered a potential new treatment for IBS, since it ameliorates hypersensitivity, visceral hyperalgesia, and inflammation. These anti-inflammatory effects could be related to its action on mast cells since it significantly inhibited the β-Hexosaminidase production in RBL-2H3 cells. ![]() Additionally, SHE enhanced immune status by downregulating of the expression of the pro-inflammatory mediators Il-1β, Il-6, Ifn-γ, Tlr-4, and the inducible enzyme Cox-2, thus inducing visceral analgesia, and promoting the restore of the gut barrier function by upregulating the mucins Muc-2 and Muc-3. Results: SHE improved referred pain and visceral hypersensitivity. Moreover, several gut hypersensitivity and hyperalgesia determinations were performed. Rats were then treated with SHE (100 mg/kg) or gabapentin (70 mg/kg) and different inflammatory and gut barrier integrity markers were evaluated. Materials and methods: IBS was provoked by deoxycholic acid (DCA). Recently, SHE has generated a great interest for irritable bowel syndrome (IBS) management, probably due to its intestinal anti-inflammatory properties shown in experimental colitis and the fact that its active components could preserve the intestinal barrier integrity, which is altered in patients with IBS.Īim of study: We aimed to test the effects of a SHE in a rat experimental model resembling human IBS. 5Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, SpainĮthnopharmacological relevance: Serpylli herba extract (SHE), composed of the aerial parts of wild thyme ( Thymus serpyllum L.) ( Lamiaceae family), is traditionally used in Europe and North Africa to treat diarrhea, gastric ulcers, intestinal parasites and upper respiratory tract infections.4Centre for Pharmacognosy and Phytotherapy, UCL School of Pharmacy, University of London, London, United Kingdom.3Servicio de Digestivo, Hospital Universitario Virgen de las Nieves, Granada, Spain.2Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain.1Center for Biomedical Research (CIBM), Department of Pharmacology, University of Granada, Granada, Spain.Antonio Jesús Ruiz-Malagón 1,2 †, María José Rodríguez-Sanchez 1,2,3 †, María Jesús Rodríguez-Sojo 1,2, Teresa Vezza 1,2, Ivo Pischel 4, Francesca Algieri 1*, María Elena Rodríguez-Cabezas 1,2*, Alba Rodríguez-Nogales 1,2,3 ‡ and Julio Gálvez 1,2,5 ‡
0 Comments
Leave a Reply. |